BACKGROUND: Switching from Remicade to CT-P13 allows for significant cost savings and has been shown to be non-inferior to continued therapy with Remicade for the treatment of Crohn's disease. AIM: The aim of this work was to prospectively evaluate clinical outcomes in a cohort of patients with Crohn's disease switching from Remicade to CT-P13. METHODS: A prospective service evaluation was performed. The Harvey-Bradshaw index, CRP, faecal calprotectin and serum for infliximab/antibody levels were collected prior to patients' final Remicade infusion and at 6 and 12 months after switching to CT-P13 as part of routine clinical care. All adverse events during follow-up were also recorded. RESULTS: One hundred and ten patients on Remicade switched to CT-P13. No significant difference was observed between the Harvey-Bradshaw Index (p = 0.07), CRP (p = 0.13), faecal calprotectin (p = 0.25) or trough infliximab levels (p = 0.47) comparing before and at 6 and 12 months after the switch to CT-P13. Seven patients developed new infliximab antibodies after switching from Remicade to CT-P13. The majority of patients remained on CT-P13 at 12 months (84.5%) and the rate of adverse events and serious adverse events was 53.8 and 13.5 per 100 patient-years of follow-up, respectively. Switching to CT-P13 resulted in a cost saving of approximately 46.4%. CONCLUSION: The transition to CT-P13 from Remicade for the treatment of Crohn's disease is safe and has no negative effect on clinical outcomes at 12 months.
BACKGROUND: Switching from Remicade to CT-P13 allows for significant cost savings and has been shown to be non-inferior to continued therapy with Remicade for the treatment of Crohn's disease. AIM: The aim of this work was to prospectively evaluate clinical outcomes in a cohort of patients with Crohn's disease switching from Remicade to CT-P13. METHODS: A prospective service evaluation was performed. The Harvey-Bradshaw index, CRP, faecal calprotectin and serum for infliximab/antibody levels were collected prior to patients' final Remicade infusion and at 6 and 12 months after switching to CT-P13 as part of routine clinical care. All adverse events during follow-up were also recorded. RESULTS: One hundred and ten patients on Remicade switched to CT-P13. No significant difference was observed between the Harvey-Bradshaw Index (p = 0.07), CRP (p = 0.13), faecal calprotectin (p = 0.25) or trough infliximab levels (p = 0.47) comparing before and at 6 and 12 months after the switch to CT-P13. Seven patients developed new infliximab antibodies after switching from Remicade to CT-P13. The majority of patients remained on CT-P13 at 12 months (84.5%) and the rate of adverse events and serious adverse events was 53.8 and 13.5 per 100 patient-years of follow-up, respectively. Switching to CT-P13 resulted in a cost saving of approximately 46.4%. CONCLUSION: The transition to CT-P13 from Remicade for the treatment of Crohn's disease is safe and has no negative effect on clinical outcomes at 12 months.
Authors: Geert D'Haens; Filip Baert; Gert van Assche; Philip Caenepeel; Philippe Vergauwe; Hans Tuynman; Martine De Vos; Sander van Deventer; Larry Stitt; Allan Donner; Severine Vermeire; Frank J Van De Mierop; Jean-Charles R Coche; Janneke van der Woude; Thomas Ochsenkühn; Ad A van Bodegraven; Philippe P Van Hootegem; Guy L Lambrecht; Fazia Mana; Paul Rutgeerts; Brian G Feagan; Daniel Hommes Journal: Lancet Date: 2008-02-23 Impact factor: 79.321
Authors: Marte L Høivik; Lydia C T Buer; Milada Cvancarova; David J Warren; Nils Bolstad; Bjørn A Moum; Asle W Medhus Journal: Scand J Gastroenterol Date: 2018-05-31 Impact factor: 2.423
Authors: Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts Journal: N Engl J Med Date: 2010-04-15 Impact factor: 91.245
Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts Journal: Lancet Date: 2002-05-04 Impact factor: 79.321
Authors: Krisztina B Gecse; Barbara D Lovász; Klaudia Farkas; János Banai; László Bene; Beáta Gasztonyi; Petra Anna Golovics; Tünde Kristóf; László Lakatos; Ágnes Anna Csontos; Márk Juhász; Ferenc Nagy; Károly Palatka; Mária Papp; Árpád Patai; Lilla Lakner; Ágnes Salamon; Tamás Szamosi; Zoltán Szepes; Gábor T Tóth; Áron Vincze; Balázs Szalay; Tamás Molnár; Péter L Lakatos Journal: J Crohns Colitis Date: 2015-12-10 Impact factor: 9.071
Authors: Violeta Razanskaite; Marion Bettey; Louise Downey; Julia Wright; James Callaghan; Miles Rush; Simon Whiteoak; Sarah Ker; Kim Perry; Caron Underhill; Eren Efrem; Iftikar Ahmed; Fraser Cummings Journal: J Crohns Colitis Date: 2017-06-01 Impact factor: 9.071
Authors: Niels Vande Casteele; Reena Khanna; Barrett G Levesque; Larry Stitt; G Y Zou; Sharat Singh; Steve Lockton; Scott Hauenstein; Linda Ohrmund; Gordon R Greenberg; Paul J Rutgeerts; Ann Gils; William J Sandborn; Séverine Vermeire; Brian G Feagan Journal: Gut Date: 2014-10-21 Impact factor: 23.059
Authors: Mahmoud Ahmed Ebada; Abdelmagid M Elmatboly; Ahmed Said Ali; Ahmed Mohamed Ibrahim; Notila Fayed; Ahmed Faisal Faisal; Souad Alkanj Journal: Int J Colorectal Dis Date: 2019-09-06 Impact factor: 2.571
Authors: Lauranne A A P Derikx; Heather W Dolby; Nikolas Plevris; Laura Lucaciu; Caitlin S Rees; Mathew Lyons; Spyros I Siakavellas; Nathan Constantine-Cooke; Philip Jenkinson; Shanna Su; Claire O'Hare; Laura Kirckpatrick; Lynne M Merchant; Colin Noble; Ian D Arnott; Gareth-Rhys Jones; Charlie W Lees Journal: J Crohns Colitis Date: 2021-12-18 Impact factor: 9.071
Authors: Jurij Hanzel; Jeroen M Jansen; Rinze W F Ter Steege; Krisztina B Gecse; Geert R D'Haens Journal: Inflamm Bowel Dis Date: 2022-03-30 Impact factor: 5.325